Abstract:Potential mechanisms for the realization of the neuroprotective action of nicotinamide during acute lethal short-term hypoxia were evaluated based on current knowledge about its effect on metabolic processes. Attention was drawn to the role of mitochondrial dysfunction and excitotoxicity followed by axonal degeneration and apoptosis of neurocytes and neuroglia during the development of an inflammatory response in trauma and cerebral ischemia. A decrease in the level of ATP in the cells during hypoxia affects the generation of the mitochondrial membrane potential, promotes an increase in membrane permeability, the release of NAD from mitochondria, the entry of sodium into the cell, and the development of intracellular edema. Activation of poly (ADP-ribose)-polymerase 1, induced by DNA damage during reoxygenation, reduces the level of NAD in the cell as a substrate for its reaction and causes dysfunction of the respiratory mitochondrial complex. High doses of nicotinamide have neuroprotective properties in traumatic brain injury, ischemia and stroke, as well as in neurodegenerative Alzheimer's, Parkinson's and Huntington's diseases. It is generally accepted that the neuroprotective effect of nicotinamide, firstly, is because, being a substrate for the synthesis of nicotinamide mononucleotide and NAD + , it can maintain and prevent the NAD + content decrease under conditions of acute hypoxia. Secondly, nicotinamide, being a blocker of poly (ADP-ribose) polymerase 1, can provide the required level of NAD + in the cell and reduce its use in the reactions with this polymerase. Thirdly, nicotinamide is a substrate for NAD + synthesis and maintains the NAD + /NADH complex, which is important for the functioning of the antioxidant system of the mitochondrial respiratory chain under conditions of acute hypoxia. It is doubtful that these mechanisms are sufficient to implement the action of nicotinamide for the reason that there was no decrease in the level of NAD in mitochondria during the death of animals under conditions of short-term lethal hypoxia. A variant of the mechanism of nicotinamide action through GABA/benzodiazepine receptors, which causes inhibition of the activation of neurocyte glutamate receptors during acute hypoxia, was considered. In hypoxia, there is an excessive hyperactivation of glutamate receptors and the development of acute cellular hypoxia, which leads to cell death from overexcitation (excitotoxicity). Nicotinamide reduces the death of neurocytes from excitotoxicity by acting on benzodiazepine receptors. GABA agonists prevent the effect of glutamate during excitotoxicity in this way.

Therapeutic Effect of Nicotinamide Mononucleotide for Hypoxic–Ischemic Brain Injury in Neonatal Mice

Nicotinamide adenine dinucleotide treatment confers resistance to neonatal ischemia and hypoxia: effects on neurobehavioral phenotypes

Nicotinamide Forestalls Pathology and Cognitive Decline in Alzheimer Mice: Evidence for Improved Neuronal Bioenergetics and Autophagy Procession

Nicotinamide mononucleotide attenuates brain injury after intracerebral hemorrhage by activating Nrf2/HO-1 signaling pathway

Acute Treatment with Nicotinamide Riboside Chloride Reduces Hippocampal Damage and Preserves the Cognitive Function of Mice with Ischemic Injury

Delayed Treatment with Nicotinamide Inhibits Brain Energy Depletion, Improves Cerebral Microperfusion, Reduces Brain Infarct Volume, but Does Not Alter Neurobehavioral Outcome Following Permanent Focal Cerebral Ischemia in Sprague Dawley Rats

β-Nicotinamide mononucleotide activates NAD+/SIRT1 pathway and attenuates inflammatory and oxidative responses in the hippocampus regions of septic mice

Nicotinamide mononucleotides alleviated neurological impairment via anti-neuroinflammation in traumatic brain injury

Distribution of Nicotinamide Mononucleotide after Intravenous Injection in Normal and Ischemic Stroke Mice.

Nad Plus Administration Can Profoundly Decrease The Brain Injury Induced By Hypoxia-Ischemia

Pre-emptive Short-term Nicotinamide Mononucleotide Treatment in a Mouse Model of Diabetic Nephropathy

Regenerative Neurogenesis after Ischemic Stroke Promoted by Nicotinamide Phosphoribosyltransferase–Nicotinamide Adenine Dinucleotide Cascade

Nicotinamide Mononucleotide Adenylyltransferase 1 Regulates Cerebral Ischemia–Induced Blood–Brain Barrier Disruption Through NAD+/SIRT1 Signaling Pathway

Abstract 12474: Nicotinamide Restores Tissue Nad + and Improves Outcomes in a Murine Model of Cardiac Arrest

Nicotinamide Improves Cognitive Function in Mice With Chronic Cerebral Hypoperfusion

Nicotinamide mononucleotide (NMN) supplementation promotes neurovascular rejuvenation in aged mice: transcriptional footprint of SIRT1 activation, mitochondrial protection, anti-inflammatory, and anti-apoptotic effects

Nicotinamide Mononucleotide Protects against Retinal Dysfunction in a Murine Model of Carotid Artery Occlusion

Nicotinamide Riboside, an NAD + Precursor, Protects Against Cardiac Mitochondrial Dysfunction in Fetal Guinea Pigs Exposed to Gestational Hypoxia

Nicotinamide mononucleotide pretreatment improves long-term isoflurane anesthesia-induced cognitive impairment in mice

NAD Replenishment with Nicotinamide Mononucleotide Protects Blood-Brain Barrier Integrity and Attenuates Delayed Tissue Plasminogen Activator-Induced Haemorrhagic Transformation after Cerebral Ischaemia.

Analysis of the Effect of Exogenous Nicotinamide on Bioenergetic Processes in the Brain During Acute Hypoxia